Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Left Atrium Role in Secondary Mitral Regurgitation
Author(s): Markos Koukos , Yannis Dimitroglou , Dimitrios Tsartsalis , et al Added: 1 year ago

Vascular Disease and Surgery

Imaging & Diagnostics
THT 2024
Start date: Mar 06, 2024 End date: Mar 04, 2024
The CardioVascular Research Foundation (CRF) proudly organizes Technology and Heart Failure Therapeutics (THT) 2024.This conference offers a unique perspective by uniting device- and technology-based therapies with drug-based approaches, effectively bridging gaps in current practices. Attendees can expect comprehensive updates on the status of treatments for heart failure, spanning drug and… View more

Heart Failure
TCT Connect
TCT Transcatheter Cardiovascular Therapeutics (TCT) is organised by Radcliffe Cardiology partner CardioVascular Research Foundation (CFR).TCT provides physicians opportunities for hands-on training, interactive learning, live case demonstrations, and to network, all with access to world-class KOLs and experts! View more
Travere Therapeutics
Richard Balasubramaniam
Job title: Consultant Cardiologist & EP, and Clinical Lead for Cardiac Rhythm Management at University Hospitals Dorset
Dr Richard Balasubramaniam is a Consultant Cardiologist & EP, and Clinical Lead for Cardiac Rhythm Management at University Hospitals Dorset, UK.Dr Balasubramaniam graduated from the University of Birmingham in 1996, having been a winner of the Aesculapius Prize for services to medicine, and trained in Cardiology at Papworth Hospital, Cambridge before pursuing a fellowship in Electrophysiology… View more
New Horizons in Dyslipidaemia 2026
Start date: Feb 12, 2026 End date: Feb 12, 2026
New Horizons in Dyslipidaemia is a free-to-access, one-day virtual educational event on 12 February 2026, developed for healthcare professionals involved in cardiovascular risk assessment and lipid management.The programme will explore the rapidly evolving landscape of lipid management, addressing gaps between perceived and actual cardiovascular risk and the underutilisation of effective… View more

Prevention & Chronic Conditions
AHA 24: The LIBerate-HeFH_OLE Study
Author(s): Frederick Raal Added: 1 year ago
AHA Conference 2024 - Long-term safety and efficacy outcomes of lerodalcibep, a third generation PCSK9 inhibitor (LIB Therapeutics LLC), in heterozygous familial hypercholesterolemia (HoFH) subjects.Prof Frederick Raal (University of the Witwatersrand, ZA) joins us onsite at AHA Conference to discuss the findings from LIBerate-HeFH_OLE (NCT04798430; LIB Therapeutics).LIBerate-HeFH_OLE is an open… View more

Prevention & Chronic Conditions
ESC 25: The KARDIA-3 Study
Author(s): Neha Pagidipati Added: 5 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating… View more

Prevention & Chronic Conditions
New Horizons in Dyslipidaemia 2026
Added: 1 month ago Source:  Radcliffe CVRM
Radcliffe Cardiology has announced New Horizons in Dyslipidaemia 2026, a live virtual event on 12 February 2026 (14:00–17:55 GMT) that will convene twelve international leaders to examine how lipid management is evolving, and where current practice continues to fall short.Despite the availability of highly effective lipid-lowering therapies, residual cardiovascular risk remains common. At the… View more

Guidelines & Statements

Prevention & Chronic Conditions
Treatment Landscape for Cardiac Amyloidosis with Dr Sarah Cuddy
Author(s): Added: 5 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly… View more

Heart Failure